{"result": "(\"entity\"<|>ENFERMEDAD CELIACA<|>EVENT<|>Enfermedad celíaca es una condición médica que se caracteriza por una reacción adversa al gluten, afectando el intestino delgado y causando diversos síntomas digestivos y no digestivos.)\n##\n(\"entity\"<|>GLUTEN<|>ORGANIZATION<|>Gluten is a protein found in wheat and related grains that can trigger adverse reactions in individuals with celiac disease.)\n##\n(\"entity\"<|>PROLAMINAS<|>ORGANIZATION<|>Prolamins are a group of plant storage proteins, including gluten, that can be toxic to individuals with celiac disease.)\n##\n(\"entity\"<|>GLIADINAS<|>ORGANIZATION<|>Gliadins are a type of prolamin found in wheat that is known to trigger immune responses in celiac disease patients.)\n##\n(\"entity\"<|>AVENINA<|>ORGANIZATION<|>Avenin is a prolamin found in oats, which may also affect individuals with celiac disease.)\n##\n(\"entity\"<|>HORDEINAS<|>ORGANIZATION<|>Hordeins are prolamins found in barley that can be harmful to those with celiac disease.)\n##\n(\"entity\"<|>ZEINA<|>ORGANIZATION<|>Zein is a prolamin found in corn that may have immunogenic effects in some individuals.)\n##\n(\"entity\"<|>SECALINAS<|>ORGANIZATION<|>Secalins are prolamins found in rye that can trigger reactions in celiac disease patients.)\n##\n(\"entity\"<|>PÉPTIDOS TOXICOS<|>ORGANIZATION<|>Toxic peptides are fragments of gluten proteins that can cause adverse reactions in individuals with celiac disease.)\n##\n(\"entity\"<|>PÉPTIDOS NO-TOXICOS<|>ORGANIZATION<|>Non-toxic peptides are fragments of gluten proteins that do not trigger adverse reactions in individuals with celiac disease.)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>GLUTEN<|>Celiac disease is directly caused by the ingestion of gluten, leading to various health issues.<|>10)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>PROLAMINAS<|>Celiac disease is associated with adverse reactions to prolamins, including gluten.<|>9)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>GLIADINAS<|>Gliadins are a specific type of prolamin that triggers immune responses in celiac disease patients.<|>10)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>AVENINA<|>Avenin, found in oats, may also affect individuals with celiac disease, although its effects can vary.<|>6)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>HORDEINAS<|>Hordeins, found in barley, can trigger reactions in those with celiac disease.<|>7)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>ZEINA<|>Zein, found in corn, may have immunogenic effects in some individuals with celiac disease.<|>5)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>SECALINAS<|>Secalins, found in rye, can also trigger reactions in celiac disease patients.<|>7)\n##\n(\"relationship\"<|>GLUTEN<|>PÉPTIDOS TOXICOS<|>Toxic peptides are derived from gluten and are responsible for the adverse reactions in celiac disease.<|>9)\n##\n(\"relationship\"<|>GLUTEN<|>PÉPTIDOS NO-TOXICOS<|>Non-toxic peptides are fragments of gluten that do not cause adverse reactions in celiac disease patients.<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: GLUTEN                      Globulinas\n                                                                         80-909\n                                                                     Sctoilvacon\n                                                       PROLAMINAS                     Gluteninas\n                                       Péptidos tóxicos          Péptidos no-tóxicos\n                                          Gliadinas (trigo)          Avenina (avena)               Dudoso efecto\n                                        Hordeínas (cebada)            Zeína (maíz)               inmunogénico\n                                        Secalinas (centeno)\n                  Figura 1.   Caracterización de los péptidos tóxicos de los cereales en la enfermedad celiaca.\n\n\n\ncapítulo está limitado a la enfermedad celiaca, no se re-                      sin restricción de gluten. Esta situación se presenta en\nvisará este aspecto en mayor profundidad8.                                     casos de celiacos en la infancia que recuperan casi to-\n                                                                               talmente su capacidad de ingerir gluten o en pacientes\n2.   Manifestaciones clínicas de la enfermedad                                 que aún no han desarrollado la enfermedad pero po-\n     celiaca                                                                   drían hacerlo en el futuro, como familiares de pacien-\n                                                                               tes celiacos con factores genéticos favorables que fue-\n2.1.   Manifestaciones digestivas                                              ron estudiados en el pasado descartándose la presencia\n   Clásicamente se dividen en tres formas clínicas 9                           de la lesión intestinal pero que posteriormente la desa-\n                                                                               rrollaron.\n(tabla 1).\n2.1.1.    Enfermedad celiaca clásica                                           2.1.3.    Enfermedad celiaca potencial\n   Caracterizada por la tríada diarrea, pérdida de peso                          Pacientes con riesgo de desarrollar la enfermedad\n                                                                               (genética e inmunidad) pero que nunca han tenido clí-\ny dolor abdominal junto con anemia ferropénica y dé-                           nica o lesión histológica sugestiva de esprúe.\nficits vitamínicos asociados y la recuperación de los sín-\ntomas y atrofia intestinal al retirar el gluten de la dieta                    2.1.4.    Enfermedad celiaca subclínica o silente\nen un período de semanas a meses.\n   La presentación clínica clásica en la infancia se caracte-                    Formas clínicas con síntomas escasos e inespecíficos,\nriza por el retraso en el desarrollo estaturo-ponderal aso-                    como anemia o cansancio, o incluso completamente\nciado a vómitos y diarrea, decaimiento general, hipoal-                        asintomáticos; detectados por la mayor difusión de\nbuminemia franca con ascitis y cambios generales como                          test inmunológicos de diagnóstico. Es muy importante\napatía e irritabilidad. En el adulto usualmente manifiesta                     su detección y corrección precoz para reducir el riesgo\ndiarrea, pérdida de peso y anemia. La intensidad de la                         de complicaciones relacionadas como la aparición de\nlesión histológica de la mucosa intestinal no se relaciona                     neoplasias, pequeños déficits nutricionales, abortos,\nnecesariamente con la severidad de los datos clínicos. La                      desarrollo de enfermedades autoinmunes, etc. A veces\nausencia de respuesta a la eliminación del gluten suele                        son las enfermedades asociadas las que ponen en la\ndeberse mayoritariamente a la falta de adherencia a la                         pista de una posible EC, como la diabetes mellitus 1\ndieta, aunque también se asocia con la presencia de es-                        (6-8 %), patología autoinmune tipo enfermedad de\nprúe colágeno o linfoma asociado a esprúe.                                     Sjögren, patología tiroidea, cuadro de malnutrición\n                                                                               proteica y déficit de ácido fólico y vitamina B12 sin cau-\n2.1.2.    Enfermedad celiaca latente                                           sa conocida, osteoporosis-osteomalacia, infertilidad o\n                                                                               abortos de repetición.\n   Pacientes que presentan una biopsia intestinal nor-                           Es en este apartado donde es necesario hace un es-\nmal y escasos o nulos síntomas consumiendo una dieta                           fuerzo importante de diagnóstico para separar de los\n---\n 292      BLOQUE: PROTEÍNAS Y AMINOÁCIDOS\n\n\n\nTabla 1.    Formas clínicas de enfermedad celiaca.\n\n\n\n                                                           Latente                                                          Sensibilidad al\n   Enfermedad celiaca            Clásica                                              Potencial         Subclínica        gluten no celiaca\n                                                   Previa             Actual\n  Clínica                            Sí              No               Sí/No                No              No/Sí                    Sí\n  Genética                           Sí               Sí                Sí                 Sí                Sí                     No\n  Lesión histológica                 Sí          No/Sí en           No/Sí en               No                Sí                     No\n  actual                                          pasado              futuro\n  Autoinmunidad                      Sí              No                 Sí                 Sí                Sí                     No\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}